Skip to main content
Premium Trial:

Request an Annual Quote

Merck, Burning Rock Ink Liquid Biopsy Companion Diagnostics Deal

NEW YORK – Burning Rock Biotech said Thursday that it has entered a strategic partnership with Merck to develop a companion diagnostic for the MET inhibitor tepotinib (Tepmetko) in the mainland China market, using Burning Rock's OncoCompass Target panel.

Tepotinib is an oral MET inhibitor approved for the treatment of advanced non-small cell lung cancer harboring MET gene alterations.

Burning Rock's OncoCompass Target is a blood-based next-generation sequencing assay that targets 168 clinically actionable predictive biomarkers, including MET. It is one of several fixed-panel NGS assays offered by the company for use in precision oncology.

The Guangzhou, China-based firm is also developing technology for early cancer detection and minimal residual disease detection, with its first launches planned for next year.

Financial terms of the agreement with Merck were not disclosed.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.